Accordingly, CTCL patients treated with mogamulizumab observed a decreased number of CCR4+ Tregs that may be instrumental for boosting immunity via restoring NK cell and CD8 T cell function (128). The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.